Balancing tissue and tumor formation in regenerative medicine

Science Translational Medicine

Volumn 4, Issue 147, 2012, Pages

  Bailey, Alexander M ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; CARCINOGENESIS; CARCINOGENICITY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL RENEWAL; EMBRYONIC STEM CELL; HUMAN; MALIGNANT TRANSFORMATION; MESENCHYMAL STEM CELL; NONHUMAN; PATIENT SAFETY; PHENOTYPIC PLASTICITY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REGENERATIVE MEDICINE; RISK BENEFIT ANALYSIS; SHORT SURVEY;

ANIMALS; BIOLOGICAL AGENTS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; REGENERATIVE MEDICINE; TISSUE ENGINEERING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84865133433     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003685     Document Type: Short Survey

References (9)

1. J. A. Thomson, J. Itskovitz-Eldor, S. S. Shapiro, M. A. Waknitz, J. J. Swiergiel, V. S. Marshall, J. M. Jones, Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147 (1998).
2. A. H. Brivanlou, F. H. Gage, R. Jaenisch, T. Jessell, D. Melton, J. Rossant, Stem cells. Setting standards for human embryonic stem cells. Science 300, 913-916 (2003).
3. K. E. Hatzistergos, A. Blum, T. Ince, J. M. Grichnik, J. M. Hare, What is the oncologic risk of stem cell treatment for heart disease? Circ. Res. 108, 1300-1303 (2011).
4. N. Grigoriadis, A. Lourbopoulos, R. Lagoudaki, J. M. Frischer, E. Polyzoidou, O. Touloumi, C. Simeonidou, G. Deretzi, J. Kountouras, E. Spandou, K. Kotta, G. Karkavelas, N. Tascos, H. Lassmann, Variable behavior and complications of autologous bone marrow mesenchymal stem cells transplanted in experimental autoimmune encephalomyelitis. Exp. Neurol. 230, 78-89 (2011).
5. Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals, Center for Biologics Evaluation and Research (CBER), FDA (1993). http://www.fda.gov/downloads/biologicsbloodvaccines/safetyavailability/ ucm162863.pdf.
6. Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy. CBER, FDA (1998). http://www. fda.gov/biologicsbloodvaccines/ guidancecomplianceregulatoryinformation/guidances/cellularandgenetherapy/ ucm072987.htm.
7. Committee for Advanced Therapies (CAT), Reflection Paper on Stem Cell-Based Medicinal Products European Medicines Agency (2010). http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/ 02/WC500101692.pdf.
8. Cellular Products for Joint Surface Repair - March 2005. Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) Meeting #38 (2005). http://www.fda.gov/ohrms/dockets/ac/05/questions/2005-4093q1.pdf.
9. Cellular Therapies Derived from Human Embryonic Stem Cells - Considerations for Pre-Clinical Safety Testing and Patient Monitoring - April 2008. Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) Meeting #45 (2008). http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-0471B1-1.pdf.